Finch Therapeutics Correlations
The correlation of Finch Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Finch |
The ability to find closely correlated positions to Finch Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Finch Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Finch Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Finch Therapeutics Group to buy it.
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Finch Pink Sheet performing well and Finch Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Finch Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HOWL | 2.78 | (0.53) | 0.00 | 2.86 | 0.00 | 6.08 | 23.66 | |||
| EWTX | 2.65 | (0.45) | 0.00 | (0.93) | 0.00 | 4.89 | 17.09 | |||
| DBTX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CELC | 3.09 | (0.14) | 0.00 | 0.15 | 0.00 | 6.28 | 21.63 | |||
| CCCC | 3.36 | (0.86) | 0.00 | (0.31) | 0.00 | 6.86 | 19.46 | |||
| IKNA | 2.10 | (0.25) | 0.00 | (0.44) | 0.00 | 4.65 | 16.13 | |||
| DSGN | 4.19 | (0.32) | 0.00 | (0.29) | 0.00 | 8.72 | 24.91 | |||
| XLO | 7.40 | 0.69 | 0.08 | 6.33 | 7.55 | 11.46 | 137.08 | |||
| ELYM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| GLUE | 3.58 | (0.35) | 0.00 | (0.27) | 0.00 | 7.34 | 30.08 |
View Finch Therapeutics Related Equities
| Risk & Return | Correlation |
Finch Therapeutics Corporate Management
| MD MBA | Chief Officer | Profile | |
| Lance CPA | Chief Officer | Profile | |
| Bryan MBA | Chief Officer | Profile | |
| Sonia Timberlake | VP Research | Profile | |
| CFA CFA | Principal COO | Profile | |
| Mark Smith | CEO Director | Profile | |
| Alka Batycky | Chief Officer | Profile |
Still Interested in Finch Therapeutics Group?
Investing in delisted pink sheets can be risky, as the pink sheet is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.